Clinica Baviera (CBAV) AI Stock Analysis

• Market Cap: €684.75M
• Dividend Yield: 3.33%
• Average Volume (3M): 2.20K
• Price to Earnings (P/E): 16.8
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: ES
• Employees: 1,706
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.34
• Shares Outstanding: 16,307,580
• 10 Day Avg. Volume: 2,444
• 30 Day Avg. Volume: 2,202
• PEG Ratio: 1.07
• Price to Book (P/B): 5.24
• Price to Sales (P/S): 1.93
• P/FCF Ratio: 14.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: €53.00 ▲(12.29% Upside)

Clinica Baviera's overall stock score is driven by its strong financial performance, characterized by robust profitability and efficient cash flow management. The technical analysis indicates bullish momentum, although the stock is in overbought territory. The valuation is reasonable but not particularly attractive, which slightly tempers the overall score.

Positive Factors

Cash Flow Management

Strong cash flow management ensures liquidity and financial flexibility, enabling the company to invest in growth opportunities and withstand economic fluctuations.

Profitability

High profitability margins indicate effective cost management and pricing power, supporting long-term business sustainability and shareholder returns.

Financial Stability

Low leverage reduces financial risk, providing stability and the ability to navigate economic downturns without significant financial strain.

Negative Factors

Revenue Growth Slowdown

Slowing revenue growth could indicate market saturation or increased competition, potentially limiting future expansion and profitability.

Market Saturation

Slower growth may suggest that the market for ophthalmological services is becoming saturated, challenging future revenue expansion.

Lack of Recent Developments

A lack of recent corporate developments could imply stagnation in innovation or strategic initiatives, potentially impacting competitive positioning.

Clinica Baviera Business Overview & Revenue Model

Company Description

Clinica Baviera (CBAV) is a leading provider of ophthalmological services in Spain and several other countries, specializing in vision correction procedures such as LASIK and cataract surgery. The clinic operates a network of medical centers equipped with advanced technology and staffed by highly trained professionals to deliver quality eye care. In addition to surgical interventions, Clinica Baviera offers comprehensive eye examinations, diagnostic services, and post-operative care, focusing on improving patients' quality of life through enhanced vision.

How the Company Makes Money

Clinica Baviera generates revenue primarily through its core services, including laser eye surgeries, cataract surgeries, and other ophthalmological treatments. The company charges patients for these procedures, which often involve significant fees due to the advanced technology and expertise required. Additional revenue streams include consultations, eye examinations, and the sale of vision correction products such as contact lenses and glasses. CBAV has established partnerships with insurance companies, allowing patients to access services through their health plans, which can increase patient volume and overall revenue. Moreover, the company invests in marketing strategies to attract new clients and enhance brand visibility, contributing to its financial performance.

Clinica Baviera Financial Statement Overview

Summary

Clinica Baviera demonstrates strong financial health with robust profitability, efficient operations, and effective cash flow management. The company maintains a low leverage position, enhancing its financial stability. While revenue growth has slowed, the company continues to generate strong returns on equity and manage its cash flows effectively.

Income Statement

Clinica Baviera shows strong profitability with a consistent gross profit margin above 80% and a healthy net profit margin around 14% to 16%. The revenue growth rate is positive, indicating steady growth, although it has slowed compared to previous years. EBIT and EBITDA margins are robust, reflecting efficient operations.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.10 in the TTM period, indicating low leverage and financial stability. Return on equity is strong at over 40%, showcasing effective use of equity to generate profits. The equity ratio is healthy, suggesting a solid capital structure.

Cash Flow

Clinica Baviera exhibits strong cash flow management with a significant free cash flow growth rate of 57% in the TTM period. The operating cash flow to net income ratio is above 1, indicating good cash generation relative to net income. Free cash flow to net income ratio is also solid, reflecting efficient cash utilization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	285.85M	262.65M	224.92M	198.45M	172.73M	122.63M
Gross Profit	229.76M	232.08M	197.85M	172.95M	151.25M	107.37M
EBITDA	80.46M	78.11M	67.22M	56.15M	53.49M	34.27M
Net Income	39.10M	40.20M	35.97M	29.52M	27.39M	13.94M
Balance Sheet
Total Assets	222.25M	211.95M	178.64M	150.10M	133.81M	120.92M
Cash, Cash Equivalents and Short-Term Investments	40.16M	38.58M	51.24M	38.99M	32.27M	26.94M
Total Debt	8.94M	63.47M	47.41M	47.81M	51.56M	54.84M
Total Liabilities	130.71M	113.59M	86.37M	81.74M	78.42M	76.02M
Stockholders Equity	90.54M	96.92M	91.00M	67.34M	54.60M	44.49M
Cash Flow
Free Cash Flow	42.11M	36.25M	35.13M	39.35M	36.28M	23.64M
Operating Cash Flow	66.88M	62.76M	57.81M	53.38M	46.86M	31.46M
Investing Cash Flow	-12.35M	-20.90M	-44.31M	-12.56M	-17.08M	-21.40M
Financing Cash Flow	-53.11M	-39.91M	-24.37M	-31.45M	-30.80M	-3.15M

Clinica Baviera Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 47.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Positive. The current price of 47.2 is above the 20-day moving average (MA) of 42.25, above the 50-day MA of 42.05, and above the 200-day MA of 39.90, indicating a bullish trend. The MACD of 0.89 indicates Negative momentum. The RSI at 74.78 is Negative, neither overbought nor oversold. The STOCH value of 91.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:CBAV.

Clinica Baviera Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	78 Outperform	€1.46B	13.86	14.89%	3.90%	11.04%	8.29%
NTH	73 Outperform	€125.89M	12.31	38.28%	11.57%	-4.18%	4.98%
CBAV	73 Outperform	€684.75M	16.84	45.95%	3.33%	―	―
PRM	73 Outperform	€227.12M	―	―	3.19%	―	―
RJF	65 Neutral	€221.33M	49.72	2.03%	1.82%	-1.19%	-54.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATRY	42 Neutral	€241.61M	-9.82	-9.43%	―	15.90%	37.03%